Tribenzylamine is a tertiary amine synthesized through the reaction of benzaldehyde with benzyl amine in the presence of a reducing agent like sodium borohydride. It is a colorless crystalline solid with a characteristic amine odor. Tribenzylamine is commonly used as a catalyst in organic synthesis, particularly in the synthesis of polymers and pharmaceuticals. It serves as a precursor for the production of various amine-containing compounds, including tribenzylammonium salts, which are valuable intermediates in pharmaceutical and material science research. While not particularly active pharmacologically, its structural features and synthetic versatility make it a valuable tool in chemical research. The study of tribenzylamine and its derivatives is ongoing, focusing on its potential applications in areas such as catalysis, polymer chemistry, and materials science.'
tribenzylamine: isolated from Humulus lupulus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Humulus | genus | A plant genus in the CANNABACEAE family. Best known for the buds of Humulus lupulus L. used in BEER.[MeSH] | Cannabaceae | A plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 24321 |
| CHEMBL ID | 3184803 |
| SCHEMBL ID | 134524 |
| MeSH ID | M0458647 |
| Synonym |
|---|
| n,n-dibenzyl(phenyl)methanamine |
| benzenemethanamine, n,n-bis(phenylmethyl)- |
| n,n-dibenzyl-1-phenyl-methanamine |
| tribenzylamine |
| 620-40-6 |
| tribenzylamine, >=99% |
| tribenzylamine, >=99.0% (nt) |
| n,n-dibenzyl-1-phenylmethanamine |
| FT-0652634 |
| T0341 |
| AKOS003273171 |
| unii-hz10o1931j |
| ai3-01809 |
| einecs 210-638-3 |
| hz10o1931j , |
| NCGC00256253-01 |
| dtxsid5047031 , |
| dtxcid3027031 |
| tox21_302339 |
| cas-620-40-6 |
| SCHEMBL134524 |
| n,n-dibenzyl(phenyl)methanamine # |
| CHEMBL3184803 |
| n,n,n-tribenzylamine |
| (n,n-dibenzylaminomethyl)benzene |
| n,n-bis(phenylmethyl)benzenemethanamine |
| STL453637 |
| mfcd00004773 |
| F0001-1653 |
| Q4462936 |
| SY049334 |
| AS-11949 |
| tribenzyl-amine |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| progesterone receptor | Homo sapiens (human) | Potency | 19.3115 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 61.6146 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 76.8806 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 16.4093 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.6067 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 6.8520 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 21.8617 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 19.4396 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 43.2331 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 9.6787 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||